ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Guarding Against the Dangers of Vitamin D Deficiency

Omega-3 fatty acids, vitamin D may control brain serotonin, affecting behavior and psychiatric disor...

Fatigue & Fibro Fog: Could You Have a B-12 Deficiency?

How Glutathione Can Save Your Life

New Dietary Guidelines Reverse Flawed Recommendations on Cholesterol

Long term antibiotic therapy may be an effective treatment for children co-morbid with Lyme disease ...

Anticancer Properties Of Saffron

Beyond Depression... SAMe Broad-Spectrum Protection Against Disorders Of Aging

BPA exposure linked to autism spectrum disorder, study reports

Omega-3 Fatty Acids Appear to Protect Damaged Heart After Heart Attack

 
Print Page
Email Article

Efficacy and Safety of Duloxetine [Cymbalta] in Patients with Chronic Low Back Pain - Source: Spine, May 10, 2010

  [ 50 votes ]   [ Discuss This Article ]
By Vladimir Skljarevski, MD, et al. • www.ProHealth.com • May 14, 2010


Study Design: This was a randomized, double-blind, placebo-controlled clinical trial.

Objective: To assess the efficacy and safety of duloxetine in the treatment of chronic low back pain (CLBP).

Summary of Background Data: Imbalance of serotonin and norepinephrine within modulatory pain pathways has been implicated in the development and maintenance of chronic pain. Duloxetine, a selective reuptake inhibitor of serotonin and norepinephrine, has demonstrated clinical efficacy in 3 distinct chronic pain conditions: diabetic peripheral neuropathic pain, fibromyalgia, and chronic pain because of osteoarthritis.

Methods: In this randomized double-blind trial, adult nondepressed patients with a non-neuropathic CLBP and a weekly mean of the 24-hour average pain score 4 or more at baseline (0-10 scale) were treated with either duloxetine or placebo for 13 weeks. The dose of duloxetine during first 7 weeks was 60 mg once daily.

At week 7, patients reporting less than 30% pain reduction had their dose increased to 120 mg.

The primary outcome measure was the Brief Pain Inventory (BPI) 24-hour average pain rating. Secondary measures included Roland-Morris Disability Questionnaire-24; Patient's Global Impressions of Improvement; Clinical Global Impressions-Severity (CGI-S); BPI-Severity and-Interference (BPI-I); and weekly means of the 24-hour average pain, night pain, and worst pain scores from patient diaries. Quality-of-life, safety, and tolerability outcomes were also assessed.

Results: Compared with placebo-treated patients (least-squares mean change of -1.50), patients on duloxetine (least-squares mean change of -2.32) had a significantly greater reduction in the BPI 24-hour average pain from baseline to endpoint (P = 0.004 at week 13).

Additionally, the duloxetine group significantly improved on Patient's Global Impressions of Improvement; Roland-Morris Disability Questionnaire-24; BPI-Severity and average BPI-Interference; weekly mean of the 24-hour average pain, night pain, and worst pain. Significantly more patients in the duloxetine group (13.9%) compared with placebo (5.8%) discontinued because of adverse events (P = 0.047).

The most common treatment-emergent adverse events in the duloxetine group included nausea, dry mouth, fatigue, diarrhea, hyperhidrosis, dizziness, and constipation.

Conclusion: Duloxetine significantly reduced pain and improved functioning in patients with chronic low back pain. The safety and tolerability were similar to those reported in earlier studies.

Source: Spine, May 10, 2010. PMID: 20424897, by Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Lilly Research Laboratories, Indianapolis, Indiana; Medavante Corporation, Hamilton, New Jersey; McLean Hospital & Harvard Medical School, Boston, Massachusetts; Indiana University School of Medicine, Indiana; University of California San Diego Department of Psychiatry, La Jolla, California; University of Wisconsin Medical School, Department of Neurology, Madison.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Natural Remedies

Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Optimize Your Immune System Naturally: Thymic Protein A Optimize Your Immune System Naturally: Thymic Protein A
Herbal Inflammation Management for Whole Body Health Herbal Inflammation Management for Whole Body Health
Aching Muscles? Top 10 Nutrients to Take Back Your Life Aching Muscles? Top 10 Nutrients to Take Back Your Life

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing